Welcome to our dedicated page for Barrick Mining news (Ticker: B), a resource for investors and traders seeking the latest updates and insights on Barrick Mining stock.
Barrick Mining Corporation reports developments tied to its global gold and copper mining, exploration and development portfolio. Company news commonly covers operating and financial results, mine and project updates, technical and governance matters, and capital allocation actions for common shares that trade on the NYSE under B and on the TSX under ABX.
Recurring updates include quarterly results releases, dividend declarations, share repurchase authorizations, annual meeting materials and changes in executive or board oversight. Barrick also reports on its gold assets in North America and other mining jurisdictions, including disclosures connected to major mines, development projects, reserves, production, costs, cash flow and responsible mining obligations.
Hexagon (NYSE:B) released the Robot Generation study across nine markets and 18,000 participants on March 10, 2026. The research finds robot anxiety is highest where robots are least visible (UK 52%) and lowest in high-exposure markets (South Korea 29%). Security is the top worry (51%). The study links visibility, clear purpose, and control to greater public trust and notes strong comfort with robots in factories and for dangerous tasks.
BioArctic (Nasdaq Stockholm: B) issued 78,000 Class B shares in February 2026 under the 2019/2028 stock option program. As of February 27, 2026 the company had 88,719,485 shares: 74,319,489 listed Class B and 14,399,996 unlisted Class A. A shares carry ten votes; B shares carry one vote, giving a total of 218,319,449 votes.
Contact details for investor relations are provided for further inquiries.
Barrick (NYSE:B) announced that its 2025 Annual Report, Annual Information Form and Form 40-F are now available on SEDAR+, EDGAR and Barrick's website.
The company also filed NI 43-101 technical reports for Pueblo Viejo and Kibali gold mines. Shareholders can request audited financial statements free from Investor Relations.
Barrick (NYSE:B) on February 24, 2026 appointed James J. McGuire as Chief Legal and Policy Officer and Woo Lee as Chief Global Affairs Officer. Both will report to CEO Mark Hill and join the Executive Committee. Poupak Bahamin becomes General Counsel and Chief Compliance Officer and remains on the Executive Committee.
McGuire brings over 30 years of legal experience; Lee has over 11 years at Barrick and will lead global government affairs and sovereign relationships.
BioArctic (NASDAQ Stockholm: B) will publish its fourth quarter report for October–December 2025 on 18 February 2026 at 08:00 a.m. CET. A presentation with CEO Gunilla Osswald and CFO Anders Martin-Löf will follow at 09:30 a.m. CET, including a Q&A, webcast and teleconference options.
Registration links, dial-in information, and archived webcast access are provided on the company's investor site. Contact details for investor relations are listed for follow-up.
BioArctic (NASDAQ: B) reports that Leqembi global sales were JPY 20.7 billion in Q4 2025, generating a royalty to BioArctic of SEK 127 million. This royalty rose ~31% versus Q4 2024; at constant exchange rates the SEK increase would be ~50%, reflecting currency effects.
Eisai will publish its Q3 FY2025 results on February 9, 2026 and BioArctic will publish its FY2025 report on February 18, 2026 at 08:00 CET.
Barrick (NYSE:B) reported record quarterly results for Q4 2025 with $6.00 billion revenue, operating cash flow of $2.73 billion and free cash flow of $1.62 billion. Full-year 2025 revenue was $16.96 billion, net earnings per share $2.93, and gold production 3.26 million oz.
The Board approved a new dividend framework targeting 50% of attributable free cash flow, a quarterly base dividend increase to $0.175 and declared $0.42 per share for Q4. Management will prepare an IPO of North American gold assets (NewCo), targeting completion by late 2026.
Barrick (NYSE:B) declared a $0.42 per share dividend for Q4 2025, a 140% increase versus Q3, payable March 16, 2026 to holders of record February 27, 2026. The company also announced a new dividend policy targeting a 50% annual payout of attributable free cash flow.
Barrick repurchased ~12.11 million shares in Q4 and ~51.90 million shares in 2025 (~3.0% of shares) for $1.5 billion cash, including $500 million in Q4. The new policy sets a fixed quarterly base dividend of $0.175 per share plus a year-end performance top-up.
Barrick (NYSE:B) appointed Robert Samek to its Board of Directors and named Mark Hill President and CEO, elevating him to the Board as a Non-Independent Director on Feb 5, 2026. Samek will join the Audit & Risk and Compensation committees and brings 31 years at McKinsey with leadership in mining, AI for energy and capital projects.
The Board cited Hill’s strong operational performance and said his board role will support the planned IPO process for Barrick’s North American gold assets.
Cereno Scientific (NASDAQ First North: B) is broadening the development focus of its orally administered HDAC inhibitor CS014 to pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company completed a Phase I study and plans a Phase II program aimed to start in Q1 2027. The shift intends to target a patient population with high unmet need and align CS014 with combined fibrotic and pulmonary vascular pathology to strengthen clinical and strategic positioning.